The economics of basiliximab (Simulect) in preventing acute rejection in renal transplantation.
about
Interleukin 2 receptor antagonists for kidney transplant recipientsInterleukin 2 receptor antagonists for kidney transplant recipientsThe CARI guidelines. Calcineurin inhibitors in renal transplantation: the addition of anti-CD25 antibody induction to standard immunosuppressive therapy for kidney transplant recipients.Update on pharmacoeconomics in transplantation.Induction therapy with rabbit antithymocyte globulin versus basiliximab after kidney transplantation: a health economic analysis from a German perspective.The role of basiliximab in the evolving renal transplantation immunosuppression protocol.
P2860
The economics of basiliximab (Simulect) in preventing acute rejection in renal transplantation.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
The economics of basiliximab ( ...... tion in renal transplantation.
@en
The economics of basiliximab
@nl
type
label
The economics of basiliximab ( ...... tion in renal transplantation.
@en
The economics of basiliximab
@nl
prefLabel
The economics of basiliximab ( ...... tion in renal transplantation.
@en
The economics of basiliximab
@nl
P2093
P2860
P1476
The economics of basiliximab ( ...... tion in renal transplantation.
@en
P2093
Björn Nashan
James B Chilcott
Michael W Holmes
Ronald L Akehurst
P2860
P304
P356
10.1111/J.1432-2277.2002.TB00204.X
P577
2002-09-17T00:00:00Z